ABSTRACT
In recent years oral agent therapy of diabetes has seen more therapeutic advancement than any other aspect of diabetes management. Because there are no oral agents available for treating type 1 diabetes, this topic clearly centers on the therapeutics of type 2 diabetes mellitus. A better understanding of the pathophysiology of type 2 diabetes, combined with the emergence of new agents having different pharmacological and pharmacokinetic profiles, have revolutionized the therapy of this increasingly common chronic disease. We see the opportunity for improved glucose control, reduced side effects, enhanced patient acceptance, and ultimately, reduced morbidity and mortality. However, with these new tools and the associated therapeutic options comes a new challenge for safe, effective, and cost-appropriate use by clinicians.
